Jan Törnell

  • Experienced line manager working as global Vice President Translational Science line managing a division of 150 scientists delivering excellent outcome and step change in productivity (up 50% over 3 years). Director level appointments for 10 years.
  • Extensive knowledge in driving strategy development and delivering profound change through chairing multiple global cross functional scientific groups and appointment as global head of strategy for oncology and infection. This resulted in, for example, cross disease area exploitation of drug projects and focus on targeting mechanisms driving molecularly defined cancers
  • Strong scientific background (MD, PhD) as evident by 80 peer-reviewed publications, professorship in Physiology and Editor-in-chief for an Elsevier journal.


Education, research, positions:

2011-               CEO, Innoext

2010-2011      Global Vice President Strategy, AstraZeneca Oncology (interim)

2009-2010     Global Head of Strategy & Planning, AstraZeneca Oncology/Infect

2006-2008    Global Vice President Translational Science DECS, AstraZeneca

2005-2008    Chair of multiple global AstraZeneca improvement projects (Stem

cells, Bioscience, Translational science)

1998-2008     Professor, Department of Physiology, Faculty of Medicine,

Sahlgrenska Academy

1999-2006     Director AstraZeneca Transgenics & Comparative Genomics

1996-1999     Director of Astra Transgenic Centre

1990-1996     Principal investigator at Sahlgrenska Academy, Department of

Physiology, Faculty of Medicine

1990-1996     Independent consultant

1992               Associate professor (Docent) in physiology, Faculty of Medicine,

Gotheburg University (GU)

1990-1992    Assistant professor

1990              Thesis presented. Degree: Ph D at the Faculty of Medicine, GU

1984-1990   Graduate student in Physiology, Faculty of Medicine, GU

1980‑1985   Medical studies. Degree: MD 1985